What is he best known for?
The fields of study he is best known for:
Ravindra Majeti mostly deals with Immunology, CD47, Stem cell, Haematopoiesis and Myeloid leukemia.
The study of Immunology is intertwined with the study of Transplantation in a number of ways.
His work in CD47 covers topics such as Cancer which are related to areas like Immune system.
The concepts of his Haematopoiesis study are interwoven with issues in Epigenetics and Cellular differentiation.
His biological study spans a wide range of topics, including Myeloid, Leukemia and Mutation.
His Phagocytosis research includes elements of Cancer research and Macrophage.
His most cited work include:
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells (953 citations)
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis (859 citations)
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors (748 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Cancer research, Haematopoiesis, Myeloid leukemia, Stem cell and Immunology.
He has included themes like Cancer cell, Cancer, Immunotherapy, Antigen and Myelofibrosis in his Cancer research study.
His Haematopoiesis research integrates issues from Progenitor cell, Molecular biology, Cellular differentiation and Bone marrow.
The study incorporates disciplines such as Enasidenib, Oncology, Mutation, Somatic evolution in cancer and Leukemia in addition to Myeloid leukemia.
Ravindra Majeti usually deals with Leukemia and limits it to topics linked to Myeloid and Immunophenotyping.
CD47, Antibody and B cell are among the areas of Immunology where the researcher is concentrating his efforts.
He most often published in these fields:
- Cancer research (34.01%)
- Haematopoiesis (32.99%)
- Myeloid leukemia (28.93%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (34.01%)
- Haematopoiesis (32.99%)
- Myeloid leukemia (28.93%)
In recent papers he was focusing on the following fields of study:
Ravindra Majeti focuses on Cancer research, Haematopoiesis, Myeloid leukemia, Cancer and Stem cell.
The various areas that he examines in his Cancer research study include Cancer cell, Antigen, Leukemia, CD47 and Immunotherapy.
His research links Myeloid with Leukemia.
His Haematopoiesis study incorporates themes from Progenitor cell, Cytokine, Computational biology and Bone marrow.
His Myeloid leukemia study integrates concerns from other disciplines, such as Embryonic stem cell, Synthetic lethality, Transplantation and Oncology.
His Stem cell study improves the overall literature in Cell biology.
Between 2018 and 2021, his most popular works were:
- Targeting Cancer Stemness in the Clinic: From Hype to Hope (136 citations)
- CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors (120 citations)
- Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia (95 citations)
In his most recent research, the most cited papers focused on:
His primary areas of study are Myeloid leukemia, Cancer research, Internal medicine, Oncology and Clinical significance.
His work carried out in the field of Myeloid leukemia brings together such families of science as Enasidenib, IDH2, IDH1 and Synthetic lethality.
His Cancer research research incorporates elements of Haematopoiesis, Erythropoiesis, Macrophage, Transplantation and Immunotherapy.
His study in Haematopoiesis focuses on Bone marrow failure in particular.
His Immunotherapy research is multidisciplinary, incorporating perspectives in Myeloid, T cell, Acquired immune system and CD47.
His Clinical significance study incorporates themes from Tumor microenvironment, Cancer, Cancer stem cell, Prognostic models and Clinical evaluation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
